Hyperprogression after first dose of immunotherapy in a patient with radioresistant metastasis from nonsmall cell lung cancer
| Autor: | Esther Oliva, Elia Sais, Javier A. Menendez, Joaquim Bosch-Barrera, Carmen Amalia Vásquez, Alvar Roselló |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Oncology Male Cancer Research medicine.medical_specialty Shoulder Lung Neoplasms Skin Neoplasms medicine.medical_treatment Adenocarcinoma of Lung Antibodies Monoclonal Humanized Metastasis 03 medical and health sciences 0302 clinical medicine Antineoplastic Agents Immunological Atezolizumab Radioresistance Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Pharmacology (medical) Aged Pharmacology Chemotherapy business.industry Immunotherapy medicine.disease Radiation therapy 030104 developmental biology 030220 oncology & carcinogenesis Monoclonal Adenocarcinoma business |
| Zdroj: | Anti-cancer drugs. 30(10) |
| ISSN: | 1473-5741 |
| Popis: | Immune checkpoint inhibitors (ICIs) represent a new standard of care for patients with advanced nonsmall cell lung cancer, improving overall survival compared with standard chemotherapy. However, a new pattern of response to ICIs characterized by accelerated tumor growth has been recently described, termed hyperprogressive disease (HPD). We report the case of a 73-year-old patient with advanced lung adenocarcinoma who developed HPD following treatment with a unique dose of atezolizumab for a skin metastasis that was refractory to chemotherapy and radiotherapy. Potential clinical biomarkers related to HPD to ICIs are reviewed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|